Antihyperlipidemic and Antiobesity Potential of Aquilaria agallocha and Borago officinalis in Fixed-Dose Combination; A Contingent Probe with Atorvastatin and Orlistat

(E-pub Ahead of Print)

Author(s): Rohima Oraon, Tarique Mahmood*, Arshiya Shamim, Farogh Ahsan, Mohammad Shariq, Saba Parveen, Mehtab Alam

Journal Name: Current Bioactive Compounds

Article ID: e190721191937
Become EABM
Become Reviewer
Call for Editor


Hyperlipidemia and Obesity have been an alarmingly rising health disorders for the past few decades worldwide. They eventually pave way for cardiovascular and other metabolic health risks that are manifested with elevated blood lipid levels. Atherosclerosis, Coronary artery disease and Cerebrovascular diseases, are some major complications of hyperlipidemia. The current clinically available drugs like, Statins & HMG-Co-A inhibitors have a good control on hyperlipidemia but present many insalubrious effects like myopathy & hepatotoxicity that questions their risk-benefit ratio. The current study was designed to develop a fixed-dose combination (FDC) of extracts of Aquilaria agallocha and Borago officinalis, to delve into therapeutic resources that have synergistic benefits and could overpower the adverse effects of modern therapy. These plants are well reported for cardioprotective, immunomodulatory and hepatoprotective potentials. The FDC developed with these plants was examined for its antihyperlipidemic and antiobesity potential in HFD fed animal model (Vijaya et al) for Hyperlipidemia. The extracts from leaves of Borago officinalis and Aquilaria agallocha were administered perorally for 28 days in a fixed dose combination (FDC) in HFD fed rats. The physical and the biochemical parameters; viz, the gross examination of liver, heart, heart weight/body weight ratio, atherogenic index, various hepatic & cardiac biomarker enzymes and serum lipid markers were scrutinized. The result of the study suggested that both the low and high dose of the FDC of Aquilaria agallocha & Borago officinalis has significant Anti-Hyperlipidemic and Anti-Obesity potential against High-fat diet-induced Hyperlipidemia and Obesity when compared to disease control group (at p<0.01 & p<0.001) and their effects were at par with clinically established drugs Atorvastatin & Orlistat.

Keywords: Coronary Artery Disease, Fixed dose combination, Hyperlipidemia, Myocardial Lipids, Obesity & Traditional Medicine

Rights & PermissionsPrintExport Cite as

Article Details

Article ID: e190721191937
Published on: 01 March, 2021
(E-pub Ahead of Print)
DOI: 10.2174/1573407217666210302085822
Price: $95

Article Metrics

PDF: 230